Sheryl Merkin, M.S., F.N.P., C.D.E., Sharon Movsas, M.S., R.D., C.D.E. and Joel Zonszein, M.D., C.D.E.

Dr. Zonszein is Professor of Clinical Medicine, Albert Einstein College of Medicine. All authors are staff members of the Clinical Diabetes Center of Montefiore Medical Center, New York.

Within the past 12 months, Dr. Zonszein has been on the Speakers Bureau of Merck, Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly & Co. and Novo Nordisk; Ms. Merkin has been on the Speakers Bureau of Sanofi Aventis and Novo Nordisk ; Ms. Movsas reports no commercial conflicts of interest.

Release Date: 07/24/2006
Termination Date: 07/24/2009

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• State the recommendations for glucose monitoring and diet in individuals receiving intensive insulin therapy
• Explain the basic principles of insulin replacement hormone utilizing basal/bolus regimens
• Identify the new insulins and new insulin delivery systems.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity